Abstracts tagged "interleukins (IL)"

Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Mahamudul Haque¹, Madeline McDougal ¹, Anil Singh ¹ and Salahuddin Ahmed ², ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Diamant Thaçi ¹, Kristian Reich ², Jo Lydie Lambert ³, Lars Iversen ⁴, Andrea Peserico ⁵, Ignasi Pau-Charles ⁶, Andrew Blauvelt⁷ and Christopher Griffiths ⁸, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ³Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁴Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁵Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, ⁶Almirall R&D, Barcelona, Spain, Barcelona, Spain, ⁷Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁸Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…
Abstract Number: 111 • 2019 ACR/ARP Annual Meeting
The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles
Catherine Poholek¹, Itay Raphael ² and Mandy McGeachy ², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Th17 lineage of CD4 T cells drives autoimmune diseases such as RA, SLE, IBD, and MS. The JAK2/STAT3 signaling pathway is required for…
Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Burkhard Moeller¹, Eleftherios Papagiannoulis ², Lisa Christ ³, Adrian Ciurea ⁴, Thomas Hugle ⁵, Ruediger B. Mueller ⁶, Michael J. Nissen ⁷, Almut Scherer ⁸, Godehard Scholz ³, Peter M. Villiger ¹ and Nikhil Yawalkar ³, ¹University Hospital Bern, Bern, Switzerland, ²SCQM Zurich, Zurich, Switzerland, ³Inselspital-University Hospital Bern, Bern, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵University Hospital Lausanne, Lausanne, Switzerland, ⁶Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ⁷University Hospital Geneva, Geneva, Switzerland, ⁸SCQM Foundation, Zürich, Switzerland
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
Abstract Number: 112 • 2019 ACR/ARP Annual Meeting
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Sushmita Chakraborty ¹, Ranjan Gupta ², Rinkee Kumari ¹ and Dipendra Kumar Mitra¹, ¹All India Institute of Medical Sciences, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
Mireia López-Corbeto¹, Sara Marsal¹, Andrea Pluma², Sergio Martinez², Maria Lopez-Lasanta², Agusti Sellas-Fernandez², Juan José de Agustín² and Mireia Barcelo², ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Ana-Maria Orbai¹, Amanda M. Gellett², Lisa Kerr² and Arnaud Constantin³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Hopital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting
Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis
Ana-Maria Orbai¹, Iain B. McInnes², Laura C. Coates³, M. Elaine Husni⁴, Dafna D Gladman⁵, Laure Gossec⁶, Luminita Pricop⁷, Olivier Chambenoit⁸, Xiangyi Meng⁸ and Philip J. Mease⁹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Glasgow, Glasgow, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Cleveland Clinic, Cleveland, OH, ⁵Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada, ⁶Université Pierre et Marie Curie and Hôpital Pitié-Salpêtrière, Paris, France, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
Abstract Number: 2572 • 2018 ACR/ARHP Annual Meeting
Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Luminita Pricop¹, Corine Gaillez², Gregory Ligozio³, Xuan Zhu³ and David James³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Subcutaneous secukinumab 150mg and 300mg are approved doses for the treatment of psoriatic arthritis (PsA) with the higher dose recommended for patients with anti-TNF inadequate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].